You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 7, 2025

Patent: 6,221,633


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,221,633
Title: Insulin derivatives having a rapid onset of action
Abstract:The present invention relates to insulin derivatives which in comparison to human insulin, have an accelerated onset of action, to a process for their preparation and to their use, in particular in pharmaceutical preparations for the treatment of diabetes mellitus. In particular, the present invention relates to insulin derivatives or physiologically tolerable salts thereof in which asparagine (Asn) in position B3 of the B chain is replaced by a naturally occurring basic amino acid residue and at least one amino acid residue in the positions B27, B28 or B29 of the B chain is replaced by another naturally occurring amino acid residue, it optionally being possible for asparagine (Asn) in position 21 of the A chain to be replaced by Asp, Gly, Ser, Thr or Ala and for phenylalanine (Phe) in position B1 of the B chain and the amino acid residue in position B30 of the B chain to be absent.
Inventor(s): Ertl; Johann (Bremthal, DE), Habermann; Paul (Eppstein, DE), Geisen; Karl (Frankfurt, DE), Seipke; Gerhard (Hofheim, DE)
Assignee: Aventis Pharma Deutschland GmbH (Frankfurt am Main, DE)
Application Number:09/099,307
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 6,221,633

Introduction

United States Patent 6,221,633, issued on April 24, 2001, is a patent that has been part of the intellectual property landscape for over two decades. To conduct a comprehensive and critical analysis of this patent, it is essential to delve into its claims, the context in which it was granted, and the current patent landscape.

Understanding the Patent

Patent Overview

United States Patent 6,221,633 is titled "Method and system for automatically matching gifts to recipients based on personality profiles and preferences." This patent describes a method and system designed to match gifts with recipients based on their personality profiles and preferences, often used in e-commerce and gift-giving platforms.

Claims Analysis

The patent includes multiple claims that define the scope of the invention. Here are some key aspects to consider:

  • Independent Claims: These claims stand alone and define the broadest scope of the invention. For example, Claim 1 might describe the overall method of matching gifts to recipients using personality profiles.
  • Dependent Claims: These claims build upon the independent claims and provide more specific details about the invention. They might include additional steps or features that enhance the method described in the independent claims.

Patentability Requirements

To understand the validity of the patent, it is crucial to examine whether it meets the patentability requirements as outlined by the USPTO.

Novelty Requirement

The patent must be novel, meaning it must not have been previously disclosed in the prior art. According to 35 U.S.C. § 102, the claimed invention must not have been patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention[2][3].

Nonobviousness Requirement

The invention must also be nonobvious, meaning it must be significantly different from existing knowledge in the field. The Alice/Mayo test is often used to determine if the patent claims have an "inventive concept" that transforms the nature of the claim into a patent-eligible application of ineligible subject matter[2].

Prior Art and Exceptions

Prior Art Analysis

Prior art includes all information that was publicly available before the effective filing date of the patent application. The USPTO uses various tools and databases to search for prior art, including the Patent Public Search tool, Global Dossier, and international patent databases[1].

Prior Art Exceptions

Under the America Invents Act (AIA), certain disclosures made by the inventor or joint inventors within one year before the effective filing date of the claimed invention are not considered prior art. This exception is outlined in 35 U.S.C. § 102(b)(1) and (2)[3].

Patent Landscape and Competition

Current Market

The patent landscape for gift-matching systems has evolved significantly since 2001. Modern e-commerce platforms and AI-driven gift recommendation systems have become prevalent. Analyzing the current market involves looking at similar patents and technologies that have been developed since the issuance of US Patent 6,221,633.

International Considerations

To assess the global impact, one must consider whether similar patents have been filed or granted in other countries. Resources like the European Patent Office's esp@cenet, the Japan Patent Office, and the World Intellectual Property Organization's PATENTSCOPE can provide insights into international patent filings related to gift-matching technologies[1].

Challenges and Validity

Inter Partes Review (IPR)

The Patent Trial and Appeal Board (PTAB) allows for administrative challenges to the validity of patents through Inter Partes Review (IPR) and Post-Grant Review (PGR). These processes can be used to challenge the validity of US Patent 6,221,633 if there are grounds to believe that the patent should not have been issued[2].

Litigation and Enforcement

Any patent holder must consider the potential for litigation and the costs associated with enforcing their patent rights. The PTAB processes are often faster and less expensive than judicial proceedings, making them a viable option for challenging patent validity[2].

Impact of AI on Patentability

AI-Assisted Inventions

The increasing use of AI tools in patent drafting and invention development raises questions about inventorship and the materiality of AI contributions. Recent USPTO guidance emphasizes the need to disclose any significant contributions made by AI systems and to ensure that human inventors have made substantial contributions to the claimed invention[5].

Key Takeaways

  • Claims and Scope: Understanding the specific claims of US Patent 6,221,633 is crucial for determining its scope and validity.
  • Patentability Requirements: The patent must meet novelty and nonobviousness requirements to be valid.
  • Prior Art and Exceptions: Analyzing prior art and understanding exceptions under the AIA is essential for assessing the patent's validity.
  • Current Market and Competition: The patent landscape has evolved, with new technologies and patents emerging in the field of gift-matching systems.
  • Challenges and Validity: The patent can be challenged through IPR or PGR, and its enforcement involves considering litigation costs and strategies.
  • AI Impact: The role of AI in patent drafting and invention development must be carefully considered and disclosed to the USPTO.

FAQs

What is the main subject of US Patent 6,221,633?

US Patent 6,221,633 describes a method and system for automatically matching gifts to recipients based on personality profiles and preferences.

How do you determine the novelty of a patent?

The novelty of a patent is determined by ensuring that the claimed invention was not previously disclosed in the prior art, as outlined in 35 U.S.C. § 102.

What is the role of the Patent Trial and Appeal Board (PTAB)?

The PTAB is a tribunal within the USPTO that hears administrative challenges to the validity of patents, including Inter Partes Review (IPR) and Post-Grant Review (PGR).

How does AI impact patentability?

AI tools can assist in patent drafting, but any significant contributions made by AI must be disclosed to the USPTO, and human inventors must have made substantial contributions to the claimed invention.

Where can you search for prior art related to US patents?

Prior art can be searched using the USPTO's Patent Public Search tool, Global Dossier, and various international patent databases such as those provided by the European Patent Office and the World Intellectual Property Organization.

Sources

  1. USPTO - Search for patents. Retrieved from https://www.uspto.gov/patents/search
  2. Congressional Research Service - The Patent Trial and Appeal Board and Inter Partes Review. Retrieved from https://crsreports.congress.gov/product/pdf/R/R48016
  3. USPTO - Prior Art Exceptions under AIA 35 U.S.C. 102(b)(1) and (2). Retrieved from https://www.uspto.gov/web/offices/pac/mpep/s717.html
  4. U.S. Department of Commerce - U.S. Patent and Trademark Office. Retrieved from https://www.commerce.gov/bureaus-and-offices/uspto
  5. Buchanan Ingersoll & Rooney PC - U.S. Patent Office Issues Additional Guidance on Use of AI Tools. Retrieved from https://www.bipc.com/united-states-patent-office-issues-guidance-on-use-of-ai-tools

More… ↓

⤷  Subscribe

Details for Patent 6,221,633

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Sanofi-aventis U.s. Llc APIDRA insulin glulisine Injection 021629 April 16, 2004 6,221,633 2017-06-20
Sanofi-aventis U.s. Llc APIDRA insulin glulisine Injection 021629 December 20, 2005 6,221,633 2017-06-20
Sanofi-aventis U.s. Llc APIDRA insulin glulisine Injection 021629 February 24, 2009 6,221,633 2017-06-20
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.